非那雄胺与爱普列特在前列腺增生症患者治疗中的依从性评价

The Compliance of Finasteride and Epristeride in the Treatment of Benign Prostatic Hyperplasia

目的:观察非那雄胺与爱普列特在前列腺增生症患者治疗中的依从性。方法:入选BPH患者共64例,分为非那雄胺组31例和爱普列特组33例,非那雄胺组患者每日口服非那雄胺10mg,每日1次。爱普列特组患者每日口服爱普列特5mg,早晚各1次。结果:治疗半年后,非那雄胺组有8例坚持继续服药,爱普列特组有19例坚持继续服药,且两组治疗前后的主观症状均有明显改善。非那雄胺组8例治疗前IPSS评分为26.3±1.5;治疗后IPSS评分为15.6±1.6(P<0.05);爱普列特组19例治疗前IPSS评分为27.3±1.5;治疗后IPSS评分为16.7±1.3(P<0.05),两组治疗后IPSS评分相比无统计学差异。结论:爱普列特片与非那雄胺均是治疗BPH的有效、安全的药物,但患者服用爱普列特后,临床起效较非那雄胺快。患者对爱普列特的依从性较非那雄胺更好。

Objective：To evaluate the compliance of Finasteride and Epristeride in the treatment of Benign Prostateic Hyperplasia （BPH）.Methods：64 patients diagnosed as BPH were devided into two groups：31patients was administered Finasteride 10 mg once a day;33 patients was administered Epristeride 5 mg twice a day, in the morning and evening.Results：After 6 months,8 patients in Finasteride group and 19 patients in Epristeride group continued their treatment.IPSS score was improved significantly in both groups. IPSS score was decreased from （26.3±1.5） to （15.6±1.6） in Finasteride group with 8 patients（P〈0.05）;and decreased from（27.3±1.5） to （16.7±1 .3） in Epristeride group with 19 patients（P〈0.05）.The IPSS score after the treatment were similar between the two groups.Conclusion：Epristeride and Finasteride are both effective and safe in treatment of BPH.But there are some differences,Epristeride is more rapid onset in clinical than Finasteride,and has superiority than Finasteride on compliance.